Conference Reports for NATAP

Back

13th International Workshop on Clinical Pharmacology of HIV Therapy April 16-18, 2012 Barcelona, Spain     Differential Exposure of Raltegravir Throughout Gut---associated Lymphoid Tissue: "High concentrations of raltegravir within GALT.......Raltegravir may be useful for combination with eradication strategies" - (06/12/12)   Clinical Pharmacology at the 13th Workshop on Clinical Pharmacology of HIV Therapy - Courtney V. Fletcher, Pharm.D. - (05/14/12)   Population Pharmacokinetics of Cobicistat-Boosted Elvitegravir in Adult Healthy Subjects and HIV-infected Patients - (04/18/12)   Pharmacokinetics of Elvitegravir and Cobicistat in Subjects with Severe Renal Impairment - (04/18/12)   Safety/Tolerability, Pharmacokinetics, and Boosting of Twice-daily Cobicistat Administered Alone or in Combination with Darunavir or Tipranavir - (04/18/12)   Lack of Clinically Relevant Drug Interactions Between GS-7340 and Efavirenz - (04/18/12)   Pharmacokinetics, Safety, and Tolerability of the HIV Integrase Inhibitor Dolutegravir Co-Administered with Rifabutin in Healthy Subjects - (04/18/12)   Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-Elvitegravir with Atazanavir, Rosuvastatin or Rifabutin - (04/18/12)   Pharmacokinetics of a Novel EVG/COBI/FTC/GS-7340 Single Tablet Regimen - (04/18/12)   Etravirine Has No Effect on the Pharmacokinetics of S/GSK1265744, a Novel HIV Integrase Inhibitor - (04/18/12)   Pharmacokinetics of EVG/COBI/FTC/TDF Single Tablet Regimen following Treatment with EFV/FTC/TDF (Atripla) in Healthy Subjects - (04/18/12)   Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with Hepatic Impairment - (04/18/12)   Metabolism & Drug-Drug Interaction Profile of Dolutegravir (DTG, S/GSK1349572) - (04/18/12)   Twice-Daily Cobicistat Effect Differs With Darunavir and Tipranavir - written by Mark Mascolini - (04/25/12)   Efavirenz PKs Highly Variable and Driven by CYP2B6 Genotype in Youngsters - written by Mark Mascolini - (04/25/12)   Switching to QUAD After Atripla Has No Telling Impact on Elvitegravir Levels - written by Mark Mascolini - (04/25/12)   Etravirine Levels 25% Lower With HCV Protease Inhibitor Boceprevir - written by Mark Mascolini - (04/18/12)   Lack of a clinically significant drug interaction between BMS-663068, a novel HIV-1 attachment inhibitor, and tenofovir disoproxil fumarate when administered in combination at steady state - written by Mark Mascolini - (04/17/12)   Cobicistat Doubles to Triples Exposure of GS-7340 (a Tenofovir Prodrug) and Resulting Tenofovir - written by Mark Mascolini - (04/17/12)   Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -1 - (04/17/12)   Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -2 - (04/17/12)   Etravirine With 300/100 or 400/100 mg of ATV/r in Treatment-Experienced People - written by Mark Mascolini - (04/17/12)   Darunavir/Cobicistat Formulation Yields Darunavir Level Close to Darunavir/Ritonavir - written by Mark Mascolini - (04/17/12)   No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine - written by Mark Mascolini - (04/17/12)   Raltegravir 400 mg Once Daily With Atazanavir/Ritonavir Plus 2 NRTIs - written by Mark Mascolini - (04/17/12)   Injected Rilpivirine for PrEP Stays in Plasma for 84 Days in Women and Men - written by Mark Mascolini - (04/17/12)   Rifabutin Cuts Elvitegravir Levels, But No Critical Elvitegravir Interactions With Atazanavir or Rosuvastatin - written by Mark Mascolini - (04/17/12)   Impact of Atazanavir/Ritonavir on Antifungal Depends on CYP2C19 Genotype - written by Mark Mascolini - (04/17/12)   Drug Interactions With Integrase Inhibitor Dolutegravir Identified - written by Mark Mascolini - (04/17/12)   Good Virologic Response in 10-Day Study of Festinavir, a New NRTI - written by Mark Mascolini - (04/17/12)   Efavirenz Concentrations Do Not Signal Discontinuation in Swiss Study - written by Mark Mascolini - (04/17/12)